



## NEWS RELEASE

### **Teijin Pharma Signs Licensing Agreement Giving UK Biotech Firm Exclusive Global Development and Commercialization Rights to Rheumatoid Arthritis Drug Candidate**

**Tokyo, October 23, 2025** --- [Teijin Pharma Limited](#), the core company of the [Teijin Group](#)'s healthcare business, announced today that has entered into an exclusive global licensing agreement with Elevara Medicines Limited, a UK-based biotech company. Under the terms of the agreement, Teijin Pharma grants Elevara exclusive global rights to develop, commercialize and manufacture a rheumatoid arthritis drug candidate originally discovered by Teijin Pharma. In return, Teijin Pharma receives a 10 percent equity stake in Elevara and is entitled to milestone payments totaling approximately \$30 million USD, as well as royalties based on future sales.

A drug candidate is a compound that has demonstrated enough potential in preclinical testing to be chosen for further development. The candidate licensed under this agreement is a small-molecule compound that was discovered at Teijin's Biomedical Research Institute in Hino City, Tokyo. It is code-named TCK-276. By inhibiting activity of cyclin-dependent kinases 4 and 6 (CDK4/6), this compound is expected to suppress abnormal synovial proliferation (thickening and overgrowth of the joint lining) and prevent cartilage degradation associated with rheumatoid arthritis.

This autoimmune disease, which affects approximately 0.4-0.5 percent of the population is characterized by inflammation of the synovial membrane in joints, leading to swelling and pain. In advanced stages, rheumatoid arthritis can cause joint destruction, deformation and functional impairment. Current treatments primarily aim to suppress inflammation.

Teijin Pharma has conducted Phase I clinical trials in the United States that involved both healthy adults and patients with rheumatoid arthritis to evaluate the compound's tolerability and pharmacological effects.

Elevara Medicines Limited was founded in 2025 with the mission to accelerate the development of innovative therapies in the rheumatoid arthritis field. With its high level of expertise and agility, the company is well positioned to bring TCK-276 to patients worldwide quickly. Teijin Pharma believes this agreement will significantly expand global access to new treatment options for rheumatoid arthritis, and the company will support Elevara's development of the TCK-276 compound.

Guided by its long-term vision to become "a company that solves challenges faced by patients, families, and communities in need of greater support," Teijin Pharma focuses on rare and intractable diseases. Leveraging its foundation in home healthcare, the company

aims to deliver new value by integrating pharmaceuticals and medical devices, enabling patients to receive safe and continuous treatment in the comfort of their own homes.

### **About the Teijin Group**

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people. Teijin is committed to its Purpose, "Pioneering solutions together for a healthy planet." Teijin works together with employees and external partners to achieve its Long-Term Vision, "To be a company that supports the society of the future." Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

### **Elevara Medicines**

Elevara is a clinical stage company developing new therapeutics to treat rheumatoid arthritis (RA) and other chronic inflammatory conditions. The Company's lead program, ELV001/TCK-276 is a potent, selective and well differentiated first-in-class oral CDK4/6 inhibitor which will be entering Phase 2 by the end of 2025. The ELV001/TCK-276 program is being positioned as an add-on oral therapy for RA patients with an incomplete response to a TNF inhibitor, preventing cycling between multiple immunosuppressive therapies. The company was co-founded by Weatherden (a UK based clinical advisory group) and Monograph Capital. The Company raised \$70m in a Series A in September 2025 and its investors are Sofinnova Partners, Forbion and Monograph Capital.

Visit [www.elevara.com](http://www.elevara.com)

### **Press Contact**

Corporate Communication Department

Teijin Limited

[pr@teijin.co.jp](mailto:pr@teijin.co.jp)